<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02614833</url>
  </required_header>
  <id_info>
    <org_study_id>IMP321 P011</org_study_id>
    <nct_id>NCT02614833</nct_id>
  </id_info>
  <brief_title>IMP321 as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma</brief_title>
  <official_title>AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immutep S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immutep S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed Phase IIb clinical study aims to investigate the safety and efficacy of the
      active immunotherapy IMP321 in combination (adjunctive) with paclitaxel chemotherapy in
      patients with hormone receptor-positive metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre, placebo-controlled, double-blind, 1:1 randomised Phase IIb study in
      female hormone receptor-positive metastatic breast cancer patients. The study comprises of
      two stages.

      Stage 1 is the open-label, safety run-in stage consisting of cohort 1 and 2 to confirm the
      (RPTD) of IMP321 in combination with paclitaxel.

      Stage 2 is placebo-controlled, double-blind randomisation stage, paclitaxel + IMP321 at the
      RPTD will be compared to paclitaxel + placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage 1 to determine the recommended phase two dose for the randomised phase</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 37 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the safety and tolerability of IMP321 as compared to placebo</measure>
    <time_frame>Up to 19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the overall survival (OS)</measure>
    <time_frame>Up to 48 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1: Evaluation of the pharmacokinetic e.g. Peak Plasma Concentration [Cmax]</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the change in quality of life (QOL)</measure>
    <time_frame>Up to 37 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the time to next treatment</measure>
    <time_frame>Up to 37 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of objective response rate (ORR)</measure>
    <time_frame>Up to 37 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of stable disease</measure>
    <time_frame>Up to 37 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Stage 1: assessment of Immuno-monitoring in a defined subset of 60 patients during the randomised stage</measure>
    <time_frame>Up to 37 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">241</enrollment>
  <condition>Adenocarcinoma Breast Stage IV</condition>
  <arm_group>
    <arm_group_label>Paclitaxel + IMP321 at the RPTD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The chemo-immunotherapy phase consists of 6 cycles of 4 weeks. Patient will receive weekly paclitaxel at Days 1, 8 and 15 with adjunctive treatment of study agent, either IMP321, on Days 2 and 16 of each 4-week cycle. After completion of the 6-cycle chemo-immunotherapy phase, responding or stable patients will receive study agent (IMP321) every 4 weeks during the maintenance phase for an additional period of up to 12 injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator: Paclitaxel + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The chemo-immunotherapy phase consists of 6 cycles of 4 weeks. Patient will receive weekly paclitaxel at Days 1, 8 and 15 with adjunctive treatment of study agent, placebo, on Days 2 and 16 of each 4-week cycle. After completion of the 6-cycle chemo-immunotherapy phase, responding or stable patients will receive study agent (placebo) every 4 weeks during the maintenance phase for an additional period of up to 12 injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMP321</intervention_name>
    <description>In the placebo-controlled, double-blind randomisation stage, paclitaxel + IMP321 at the RPTD will be compared to paclitaxel + placebo</description>
    <arm_group_label>Paclitaxel + IMP321 at the RPTD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>In the placebo-controlled, double-blind randomisation stage, paclitaxel + placebo will be compared to paclitaxel + IMP321 at the RPTD</description>
    <arm_group_label>Comparator: Paclitaxel + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel will be given in both treatment arms (classified as Non IMP)</description>
    <arm_group_label>Paclitaxel + IMP321 at the RPTD</arm_group_label>
    <arm_group_label>Comparator: Paclitaxel + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to give written informed consent and to comply with the protocol

          2. Metastatic oestrogen receptor positive and/or progesterone receptor positive breast
             adenocarcinoma, histologically proven by biopsy of the primary tumour and/or
             metastasis

          3. Female of age 18 years or above

          4. Patients who are indicated to received first line chemotherapy with weekly paclitaxel

          5. Evidence of measurable disease as defined by Response Evaluation Criteria version 1.1

        6 Laboratory criteria: haematology and biochemistry results within the limits normally
        expected for the patient population.

        Exclusion Criteria:

          1. Prior chemotherapy for metastatic breast adenocarcinoma

          2. Disease-free interval of less than twelve months from the last dose of adjuvant
             chemotherapy

          3. Inflammatory carcinoma

          4. Candidate for treatment with trastuzumab (or other Her2/neu targeted agents)

          5. Systemic chemotherapy, radiation therapy or any other investigational agent within 4
             weeks, endocrine therapy within 1 week prior to first dose of study treatment or
             CDK4/6 inhibitors within 5 times half-life (acc.to SPC) prior to first dose of study
             treatment and until completion of study treatment

          6. Symptomatic known cerebral and/or leptomeningeal metastases

          7. Serious intercurrent infection

          8. Evidence of severe or uncontrolled cardiac disease (NYHA III-IV) within 6 months prior
             to first dose of study treatment

          9. Active acute or chronic infection

         10. Active autoimmune disease requiring immunosuppressive therapy

         11. Previous malignancies within the last three years other than breast carcinoma

         12. Patients with prior organ or stem cell transplantation

         13. Any condition requiring continuous systemic treatment with either corticosteroids or
             other immunosuppressive medications within 4 weeks prior to first dose of study
             treatment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Immutep S.A.S</last_name>
    <role>Study Director</role>
    <affiliation>Immutep S.A.S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Immutep S.A.S Parc Club Orsay 2, rue Jean Rostand 91893 Orsay cedex France</last_name>
    <email>enquiries@immutep.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AZ Sint-Jan Burgge-Oostende</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc - Institut Roi Albert II - Cancérologie et Hématologie Oncologie clinique</name>
      <address>
        <city>Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Maarten</name>
      <address>
        <city>Duffel</city>
        <zip>2570</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen Breast and Gynecological Oncology Unit</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven, campus Gasthuisberg Department of General Medical Oncology and Multidisciplinary Breast Centre</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Sart Tilman Oncologie médicale</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte-Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GZA Ziekenhuizen campus Sint-Augustinus Oncologische Research</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie / Centre René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud - IUC Toulouse - Oncopôle</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin-Buch Gynecologic Oncology and Obstetrics, Head of the Interdisciplinary, Breast Cancer Center</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KEM- Brustzentrum der Kliniken Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus Centrum für Hämatologie und Onkologie</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NCT - Nationales Centrum für Tumorerkrankungen</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UFKT - Universitäts-Frauenklinik Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UFU - Universitätsfrauenklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szent Margit Kórház Onkológiai Osztály</name>
      <address>
        <city>Budapest</city>
        <zip>1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MH Egészségügyi Központ Onkológiai Osztály</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DE KK Onkológiai Klinika</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mór Oktató Kórház Klinikai Onkológiai Centrum Kaposvár</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <zip>2625</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zuyderland MC</name>
      <address>
        <city>Geleen</city>
        <zip>6162</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMCG Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MUMC Medical Oncology department</name>
      <address>
        <city>Maastricht</city>
        <zip>6202</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>VieCuri Medisch Centrum</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kierownik Oddziału Onkologii i Radioterapii Szpital Morski im. PCK w Gdyni</name>
      <address>
        <city>Gdynia</city>
        <zip>81 - 519</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Centre for Ophthalmology and Oncology</name>
      <address>
        <city>Katowice</city>
        <zip>PL-40-514</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specjalistyczna Praktyka</name>
      <address>
        <city>Warsaw</city>
        <zip>02-954</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Military Institute of Medicine, Oncology Dept</name>
      <address>
        <city>Warsaw</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>St James' Institute of Oncology</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust The Christie Clinic - Medical Oncology</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2015</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hormone receptor positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

